Trending news
Analyze
Pricing
Inovio Pharmaceuticals

Inovio Pharmaceuticals

Work at Inovio Pharmaceuticals? Add yourself to this profile

Inovio Pharmaceuticals

Elsewhere

Alexa global traffic share

Latest funding
Grant
$45,000,000
Employees

Unknown size

The Motley Fool

How Inovio Pharmaceuticals Is Leading the Zika Vaccine Race

The Motley Fool

Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward

The Motley Fool

Why Inovio Pharmaceuticals Inc. Is Soaring Today

The Motley Fool

1 Big Reason Why Inovio Pharmaceuticals, Inc. Was All the Buzz in April

The Motley Fool

Better Buy: Inovio Pharmaceuticals Inc. vs. Novavax Inc.

The Motley Fool

Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?

The Motley Fool

3 Reasons Why Inovio Pharmaceuticals, Inc. Was Unstoppable in March

The Motley Fool

Inovio Pharmaceuticals Won't Move Forward With Clinical Study: So What?

The Motley Fool

Better Buy: Inovio Pharmaceuticals Inc. vs. Juno Therapeutics

The Motley Fool

Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation

The Motley Fool

Is Inovio Pharmaceuticals' Zika Surge Premature?

The Motley Fool

2 Reasons Behind Inovio Pharmaceuticals, Inc.'s Tumble in 2015 --

The Motley Fool

Will 2016 Be Inovio Pharmaceuticals, Inc.'s Best Year Yet? (INO)

The Motley Fool

The Worst Inovio Pharmaceuticals, Inc. Headlines in 2015 --

The Motley Fool

The 3 Most Important Drugs in Inovio Pharmaceuticals' Pipeline --

Health Stock markets
The Motley Fool

Inovio Pharmaceuticals Produces a Rare Quarterly Profit, but Don't Get Too Excited Just Yet --

Health Stock markets Earnings
The Motley Fool

Here's Why Inovio Pharmaceuticals Had the Cure for Investors' Ills in October --

The Motley Fool

Is Inovio Pharmaceuticals a Late Bloomer? --

Health Stock markets Science